Is ORCL a buy, hold, or sell?
ORCL carries a valuation grade of Hold. The trailing P/E of 40.5 sits 26% above the Technology sector median of 32.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $138–$347 — implying a +7% margin of safety at the current price of $225.78. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 5.7% earnings surprise. Analyst estimate revisions are trending upward.
What are ORCL's key risk factors?
With a beta of 1.54, ORCL exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -32.2% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 3.2% of total portfolio loss in the worst 5% of months. Net margins stand at 25.3%. Return on equity of 57.6% indicates highly efficient capital allocation. Debt-to-equity of 415% warrants monitoring for leverage risk.
At 0.60, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 65.5% exceeds realized volatility of 56.9% by 9 points, suggesting options are pricing in elevated risk. Insiders have been net sellers to the tune of $1709.5M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 2.1% of float, suggesting limited bearish conviction.
How does ORCL fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — ORCL carries a beta of 1.54, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, ORCL shows the strongest co-movement with MSFT (0.39), SAP (0.16), AMZN (0.12). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The ORCL analysis here is a single node in that larger structure.
For analysis of the structural AI infrastructure capex cycle driving demand for ORCL — see our thematic deep-dive: The $7 Trillion Race: AI Infrastructure as a Decade-Long Investment Cycle.
